Valuation: PTC Therapeutics, Inc.

Market Cap 5.98B 5.17B 4.86B 4.42B 8.3B 572B 8.44B 56.91B 22.25B 287B 22.47B 21.98B 952B P/E 2026 *
46.9x
P/E 2027 * 26.5x
Enterprise Value 4.11B 3.55B 3.34B 3.04B 5.71B 393B 5.8B 39.11B 15.29B 197B 15.44B 15.11B 654B EV / Sales 2026 *
3.28x
EV / Sales 2027 * 2.8x
Free-Float
92.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: PTC Therapeutics, Inc.

1 day-0.38%
1 week-2.20%
Current month+5.43%
1 month-8.69%
3 months+0.32%
6 months+3.24%
Current year-5.61%
1 week 70.85
Extreme 70.85
75
1 month 64.57
Extreme 64.5675
80.56
Current year 61.43
Extreme 61.43
90.87
1 year 47.94
Extreme 47.936
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2023
Director of Finance/CFO 41 12/07/2023
Chief Tech/Sci/R&D Officer - 30/09/2017
Director TitleAgeSince
Chairman 74 31/10/2004
Chairman 80 30/03/1998
Director/Board Member 65 30/11/2005
Date Insider Type Main position Quantity % Market Cap.
04/08/26 Sell

Chief Executive Officer

-10,292 0.0124%
28/07/26 Other

Director

200,401 0.2416%
28/07/26 Free

Director

11,213 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-2.20%+46.87%+77.61% 5.98B
-2.25%-0.47%+68.30%+116.05% 1,052B
-0.66%+0.43%+47.39%+51.02% 627B
-0.54%+1.39%+20.69%+64.61% 441B
-0.03%-4.85%+38.67%+37.62% 349B
+0.42%-2.90%+22.85%+37.01% 287B
+1.24%-3.14%-1.06%+7.62% 241B
-0.63%+1.04%+40.05%+56.67% 224B
-0.59%-4.16%-15.57%-53.97% 202B
+0.16%+3.87%+16.89%+77.38% 172B
Average -0.33%-0.91%+28.51%+47.16% 360.12B
Weighted average by Cap. -0.80%-0.63%+38.75%+62.13%

Financials

2026 *2027 *
Net sales 1.26B 1.08B 1.02B 927M 1.74B 120B 1.77B 11.94B 4.67B 60.11B 4.71B 4.61B 200B 1.37B 1.18B 1.11B 1.01B 1.9B 131B 1.93B 13.02B 5.09B 65.58B 5.14B 5.03B 218B
Net income 132M 114M 107M 97.36M 183M 12.61B 186M 1.25B 490M 6.32B 495M 484M 20.99B 223M 193M 181M 165M 310M 21.36B 315M 2.12B 830M 10.69B 839M 820M 35.54B
Net Debt -1.87B -1.62B -1.52B -1.38B -2.6B -179B -2.64B -17.79B -6.96B -89.6B -7.03B -6.87B -298B -2.15B -1.85B -1.74B -1.58B -2.98B -205B -3.03B -20.4B -7.98B -103B -8.05B -7.88B -341B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
14/08/26 US$71.70 -0.38% 564,330
13/08/26 US$71.97 -0.92% 697,348
12/08/26 US$72.64 -1.44% 976,043
11/08/26 US$73.70 -1.25% 763,594
10/08/26 US$74.63 +1.80% 826,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
71.70USD
Average target price
99.29USD
Spread / Average Target
+38.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock